Direct link shown between inflammasome activation and Alzheimer’s
A new study has demonstrated that NLRP3 inflammasome directly drives tau pathology in neurodegenerative diseases and Alzheimer's disease.
List view / Grid view
A new study has demonstrated that NLRP3 inflammasome directly drives tau pathology in neurodegenerative diseases and Alzheimer's disease.
New research has found that the animal model market for disease research and therapeutic testing will exhibit strong growth.
Scientists have discovered that a plant-based compound called halofuginone activates a pathway that results in better antibodies and could improve the effectiveness of vaccines.
Researchers have created ‘three-parent flies' which can be used as a model to study mitochondrial diseases and screen potential drug compounds.
In a pre-clinical model of multiple sclerosis, orally treating susceptible mice with a microRNA from the diseased gut has prevented the disease.
Scientists have idenified that variation in a gene called Mucin 6 appears to indicate a tendency for acquiring Alzheimer’s disease.
A study has discovered that the PKM2 protein plays a role in regulating immune cells and blocking this could be a potential treatment for inflammatory diseases.
A new discovery on how the immune system responds to malaria infection could lead to better treatments for hepatitis C, HIV and lupus.
Molecular drivers of Parkinson's disease have been revealed by scientists who also determined how they impact the functions of genes involved in the condition and the results may point to potential new treatments.
On 5-6 November, ACC Liverpool hosted the ELRIG Drug Discovery event, which allowed R&D professionals to come together and discuss the latest industry developments.
A study has revealed a new antibody that reverses the effects of pulmonary arterial hypertension in rodents and cell models.
A study has shown that a group of cells called adipose B cells can become dysfunctional with age, causing metabolic conditions such as diabetes, which has provided a drug target.
Researchers have discovered that patients with alcoholic hepatitis had high numbers of a destructive gut bacterium and they were able to use a cocktail of phages to target and kill the bacteria, eradicating the disease.
A study on tuberous sclerosis complex has expanded the knowledge of the formation of this disease and how it can be targeted at the molecular level.
A new study could pave the way for developing a viable therapy for Charcot-Marie-Tooth patients affected by TyrRS mutations.